Add-on tafasitamab and lenalidomide did not negatively impact chemotherapy backbone ...

Higher rates of adverse events offset the positive survival results in an area of great unmet need. For decades, the standard ...

The addition of two agents to standard first-line treatment significantly improved PFS among patients with aggressive B-cell lymphomas, according to results of the randomized phase 3 frontMIND ...

Although ibrutinib adds to the cost of treatment, its benefits over the long term justify the cost, investigators found. Adding ibrutinib (Imbruvica) to the R-CHOP regimen (rituximab, cyclophosphamide ...

Outcomes for patients with high-risk large B-cell lymphoma (LBCL), defined by an International Prognostic Index (IPI) score ...

Tafasitamab and lenalidomide are likely to be approved with R-CHOP for frontline DLBCL, but with bispecific antibodies on the horizon, the role of the combination is uncertain.

Add Yahoo as a preferred source to see more of our stories on Google. Few agents define SoC for first-line DLBCL Treatment of refractory or relapsed (R/R) diffuse large B-cell lymphoma (DLBCL) has ...

Combined-Modality Therapy for Clinical Stage I or II Hodgkin's Lymphoma: Long-Term Results of the European Organisation for Research and Treatment of Cancer H7 Randomized Controlled Trials Untreated ...

Combined-Modality Therapy for Clinical Stage I or II Hodgkin's Lymphoma: Long-Term Results of the European Organisation for Research and Treatment of Cancer H7 Randomized Controlled Trials Untreated ...